IDEXX Laboratories Inc (IDXX)vsIllumina Inc (ILMN)
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
ILMN
Illumina Inc
$162.32
-3.42%
HEALTHCARE · Cap: $24.35B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 1% more annual revenue ($4.45B vs $4.39B). IDXX leads profitability with a 24.6% profit margin vs 19.4%. ILMN appears more attractively valued with a PEG of 2.82. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
ILMN
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Margin of Safety
+58.0%
Fair Value
$276.80
Current Price
$162.32
$114.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Every $100 of equity generates 32 in profit
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
Moderate valuation
Trading at 9.2x book value
4.8% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : ILMN
The strongest argument for ILMN centers on Return on Equity. Profitability is solid with margins at 19.4% and operating margin at 18.3%.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Bear Case : ILMN
The primary concerns for ILMN are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
IDXX profiles as a mature stock while ILMN is a value play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
ILMN generates stronger free cash flow (251M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 56/100), backed by strong 24.6% margins and 14.3% revenue growth. ILMN offers better value entry with a 58.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Illumina Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?